[
    [
        {
            "time": "2018-01-02",
            "original_text": "Chesapeake Utilities to Join S&P SmallCap 600",
            "features": {
                "keywords": [
                    "Chesapeake",
                    "Utilities",
                    "S&P",
                    "SmallCap",
                    "600"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "utilities"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Chesapeake Utilities to Join S&P SmallCap 600",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Dow Jones Finishes Week With Strong Gains; This Leaderboard Stock Is In Buy Range",
            "features": {
                "keywords": [
                    "Dow",
                    "Jones",
                    "strong gains",
                    "buy range"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow Jones Finishes Week With Strong Gains; This Leaderboard Stock Is In Buy Range",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Johnson & Johnson stock rises Friday, still underperforms market",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "stock rises",
                    "underperforms"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Johnson & Johnson stock rises Friday, still underperforms market",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Analyst Report: Johnson & Johnson",
            "features": {
                "keywords": [
                    "Analyst Report",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Analyst Report: Johnson & Johnson",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "COVID-19",
                    "vaccine",
                    "strong immune response"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "There are four coronavirus vaccines in late-stage studies — here’s how they differ",
            "features": {
                "keywords": [
                    "coronavirus",
                    "vaccines",
                    "late-stage studies"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "There are four coronavirus vaccines in late-stage studies — here’s how they differ",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Why Covid-19 Vaccine Prices May Be Unexpectedly Low",
            "features": {
                "keywords": [
                    "Covid-19",
                    "Vaccine Prices",
                    "Unexpectedly Low"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Covid-19 Vaccine Prices May Be Unexpectedly Low",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Dow Jones Up 100 Points After Early Dive; Apple, Microsoft Lead Tech Stock Rally",
            "features": {
                "keywords": [
                    "Dow Jones",
                    "Up 100 Points",
                    "Tech Stock Rally"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow Jones Up 100 Points After Early Dive; Apple, Microsoft Lead Tech Stock Rally",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "J&J: most Phase 1/2a participants in COVID-19 vaccine developed neutralizing antibodies",
            "features": {
                "keywords": [
                    "J&J",
                    "Phase 1/2a",
                    "COVID-19",
                    "neutralizing antibodies"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "J&J: most Phase 1/2a participants in COVID-19 vaccine developed neutralizing antibodies",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Dow Jones Comes Back From Early Dive; Apple, Microsoft Lead Tech Stock Rally",
            "features": {
                "keywords": [
                    "Dow Jones",
                    "Early Dive",
                    "Tech Stock Rally"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dow Jones Comes Back From Early Dive; Apple, Microsoft Lead Tech Stock Rally",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "U.S. nears 7M coronavirus cases, big pharmaceutical companies race for a vaccine",
            "features": {
                "keywords": [
                    "U.S.",
                    "coronavirus cases",
                    "pharmaceutical companies",
                    "vaccine"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "U.S. nears 7M coronavirus cases, big pharmaceutical companies race for a vaccine",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine",
            "features": {
                "keywords": [
                    "J&J",
                    "manufacturing deal",
                    "GRAM",
                    "COVID-19 vaccine"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-14",
            "original_text": "Is JNJ Stock A Buy As Pharma Giant Starts Final-Phase Coronavirus Vaccine Trials?",
            "features": {
                "keywords": [
                    "JNJ Stock",
                    "Buy",
                    "Final-Phase",
                    "Coronavirus Vaccine Trials"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is JNJ Stock A Buy As Pharma Giant Starts Final-Phase Coronavirus Vaccine Trials?",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-15",
            "original_text": "Another Covid-19 Vaccine Candidate Is in the Final Stage of Testing",
            "features": {
                "keywords": [
                    "Covid-19",
                    "Vaccine Candidate",
                    "Final Stage"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Another Covid-19 Vaccine Candidate Is in the Final Stage of Testing",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-16",
            "original_text": "Novavax Is Starting a Phase 3 Trial of Its Covid-19 Vaccine. The Stock Is Jumping.",
            "features": {
                "keywords": [
                    "Novavax",
                    "Phase 3 Trial",
                    "Covid-19 Vaccine",
                    "Stock Is Jumping"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novavax Is Starting a Phase 3 Trial of Its Covid-19 Vaccine. The Stock Is Jumping.",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-17",
            "original_text": "3 Dividend Aristocrats to Buy and Hold Forever",
            "features": {
                "keywords": [
                    "Dividend Aristocrats",
                    "Buy and Hold Forever"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3 Dividend Aristocrats to Buy and Hold Forever",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-18",
            "original_text": "Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock",
            "features": {
                "keywords": [
                    "Patient Investors",
                    "Bristol-Myers Squibb",
                    "Cheap Stock"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]